190 related articles for article (PubMed ID: 6197309)
41. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats.
Culver KE; Rosenfeld JM; Szechtman H
Psychopharmacology (Berl); 2000 Aug; 151(2-3):202-10. PubMed ID: 10972466
[TBL] [Abstract][Full Text] [Related]
42. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
Green AR; Youdim MB
Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
[TBL] [Abstract][Full Text] [Related]
43. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF
Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
[TBL] [Abstract][Full Text] [Related]
44. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Waldmeier PC
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
[TBL] [Abstract][Full Text] [Related]
45. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.
Lakshmana MK; Rao BS; Dhingra NK; Ravikumar R; Govindaiah ; Sudha S; Meti BL; Raju TR
Neurochem Res; 1998 Aug; 23(8):1031-7. PubMed ID: 9704592
[TBL] [Abstract][Full Text] [Related]
46. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.
Fowler JS; Logan J; Azzaro AJ; Fielding RM; Zhu W; Poshusta AK; Burch D; Brand B; Free J; Asgharnejad M; Wang GJ; Telang F; Hubbard B; Jayne M; King P; Carter P; Carter S; Xu Y; Shea C; Muench L; Alexoff D; Shumay E; Schueller M; Warner D; Apelskog-Torres K
Neuropsychopharmacology; 2010 Feb; 35(3):623-31. PubMed ID: 19890267
[TBL] [Abstract][Full Text] [Related]
47. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl.
Hársing LG; Vizi ES
Br J Pharmacol; 1984 Nov; 83(3):741-9. PubMed ID: 6439273
[TBL] [Abstract][Full Text] [Related]
48. The effect of N-methyl-norsalsolinol on monoamine oxidase of the rat caudate nucleus in vitro.
Moser A; Scholz J; Bamberg H; Böhme V
Neurochem Int; 1996 Jan; 28(1):109-12. PubMed ID: 8746770
[TBL] [Abstract][Full Text] [Related]
49. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
50. Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum.
Ask AL
Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):56-63. PubMed ID: 6493351
[TBL] [Abstract][Full Text] [Related]
51. Effects of low-dose 4-fluorotranylcypromine on rat brain monoamine oxidase and neurotransmitter amines.
Sherry RL; Baker GB; Coutts RT
Biol Psychiatry; 1990 Sep; 28(6):539-43. PubMed ID: 1699613
[No Abstract] [Full Text] [Related]
52. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
53. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
54. Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
Wei Z; Gabriel GG; Rui L; Cao X; Pennington PR; Chlan-Fourney J; Nazarali AJ; Baker GB; Mousseau DD
J Alzheimers Dis; 2012; 28(2):403-22. PubMed ID: 22045496
[TBL] [Abstract][Full Text] [Related]
55. N-[2-(o-iodophenoxy)ethyl]cyclopropylamine hydrochloride (LY121768), a potent and selective irreversible inhibitor of type A monoamine oxidase.
Fuller RW; Hemrick-Luecke SK; Molloy BB
Biochem Pharmacol; 1983 Apr; 32(7):1243-9. PubMed ID: 6847714
[TBL] [Abstract][Full Text] [Related]
56. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
57. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
58. Are there MAO inhibitors specific for dopamine metabolism?
Youdim MB; Holzbauer M
Adv Biochem Psychopharmacol; 1977; 16():349-58. PubMed ID: 329649
[No Abstract] [Full Text] [Related]
59. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
Waldmeier PC; Baumann PA; Feldtrauer JJ; Hauser K; Bittiger H; Bischoff S; von Sprecher G
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):305-11. PubMed ID: 1980718
[TBL] [Abstract][Full Text] [Related]
60. Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A.
Gerardy J; Dresse A
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):75-9. PubMed ID: 11853123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
